soul trial oral semaglutide cardiovascular outcomes results 2025 A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link soul trial oral semaglutide cardiovascular

Mast cells not only release histamine, but they also have receptors for estrogen

Each dose escalation can trigger a 1-3 week recurrence

2 68% of patients were at very high risk for CKD progression 2,k Patient characteristics at baseline (N=3533) 1,2 k Patients were classified as very high risk for CKD progressing according to Kidney Disease: Improving Global Outcomes (KDIGO) risk calculators based on GFR and albuminuria categories

Now my face is acne free, sometimes during period I rarely see one acne but that's all, which is huge improvement for my skin

The funding sources had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript